The Rural and Urban Supply of Clinicians with a DEA Waiver to Prescribe Buprenorphine in 2022 Prior to the Elimination of the Waiver Requirement

Link

https://familymedicine.uw.edu/wp-content/uploads/2025/04/RHRC_DBAPR2025_Woolcock.pdf

Sponsor

Federal Office of Rural Health Policy (FORHP)
Product of the Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Rural Health Research Center funded by FORHP.

Description

Summarizes data comparing rural and urban trends in the supply of clinicians with a DEA waiver to prescribe buprenorphine for the treatment of substance use disorders (SUDs) in the 5 years (2017-2022) prior to the ending of the waiver requirement. Includes information on the total number and percentage of DEA-waivered clinicians in rural and urban areas, rates of increase in waivered clinicians over time, number of treatment slots, and clinician supply rates broken down by census division and clinician type.

Date

04/2025

Geographic Coverage

Nationwide

Topics

Healthcare Workforce • Substance Use Disorder • Treatment